Posts by: admin

News

Mymetics Corporation, a US registered biotechnology company with its main office in Switzerland, has partnered with Australian biotech Imugene to manufacture and develop HER-Vaxx, a cancer immunotherapy vaccine, which is ... Read more

August 5, 2014August 5, 2014

TapImmune Highlights New Direction in Immunotherapy Technologies For Breast and Ovarian Cancer Treatment

News

TapImmune Inc., an immunotherapy company developing innovative peptide and gene-based vaccines targeting cancer and infectious diseases, has announced that Dr. Keith Knutson, PhD, has been appointed to chair the company’s ... Read more

August 4, 2014

MedImmune And Advaxis Partner on Immuno-Oncology Combo Trial

News

Biologics research company MedImmune entered into a Phase 1/2 immunotherapy clinical trial collaboration with biotechnology company Advaxis, which develops cancer immunotherapies. The study will evaluate the safety and efficacy of ... Read more

August 4, 2014August 4, 2014

Celsion Acquires EGEN, Adding RNA Therapeutics, Immunotherapy To Cancer Therapy Platform

News

Celsion Corp., a biopharmaceutical company developing mid-to-later stage therapies for cancer, recently acquired EGEN, Inc., a drug developer with a proven track record for designing innovative cancer treatments in the pharmaceutical industry. ... Read more

August 1, 2014August 1, 2014

ZIOPHARM Oncology Expands Synthetic Immuno-Oncology Programs With Intrexon, Clinical Program Update

News

ZIOPHARM Oncology, Inc., a biopharmaceutical company focused on the development of new cancer therapies, has announced the expansion of synthetic immuno-oncology programs in conjunction with Intrexon Corporation, to include chimeric ... Read more

July 30, 2014July 31, 2014

HPV Immunotherapy Drug From Inovio Pharmaceuticals Hits Primary Efficacy Endpoint in Phase II Trial For Cervical Dysplasia

News

Inovio Pharmaceuticals Inc., a biotech company developing innovative vaccine strategies to fight cancer and infectious diseases, has announced that its randomized, double-blind, placebo-controlled phase II trial of VGX-3100 successfully reached ... Read more

July 30, 2014July 30, 2014

Pancreatic Cancer Combination Immunotherapy From Aduro BioTech Receives Breakthrough Therapy Designation from FDA

News

Aduro BioTech, Inc., a clinical-stage biotechnology company focused on cancer immunotherapy, has announced its pancreatic cancer combination treatment of CRS-207 and GVAX Pancreas immunotherapies was granted Breakthrough Therapy Designation by ... Read more

July 28, 2014July 31, 2014

Bristol-Myers Squibb, Ono Pharmaceutical To Jointly Develop Opdivo, Yervoy in Asia Pac

News

Bristol-Myers Squibb Company and Ono Pharmaceutical Co., Ltd. have signed a strategic collaboration agreement to jointly develop and commercialize Opdivo (nivolumab) and Yervoy (ipilimumab) as single agents and combination regimens to help address ... Read more